Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Marwa Salah Gadallah, Mona Kandil, Nanis Shawky Holah, Gihan Ahmed Sobhy, Mohamed Mohamdy Ahmed, Shymaa Sabry El-Gammal, Nermine Ahmed Ehsan
UNLABELLED: Hepatic steatosis has become the most common cause of chronic liver disease among children worldwide. Lipophagy has been considered as a pathway affecting steatosis development and progression. OBJECTIVE: this study aimed to evaluate the immunohistochemical expression of Beclin1 and LC3A in pediatric hepatic tissues with steatosis and to correlate their expression with clinicopathological parameters. METHODS: this study included 81 Egyptian pediatric patients with hepatic steatosis and 21 pediatric cases without hepatic steatosis...
May 1, 2024: Asian Pacific Journal of Cancer Prevention: APJCP
#2
JOURNAL ARTICLE
Amy Collins, Rebecca Scott, Caroline L Wilson, Giuseppe Abbate, Gabrielle Ecclestone, Adam G Albanese, Demi Biddles, Steven White, Jeremy French, John Moir, Wasfi Alrawashdeh, Colin Wilson, Sanjay Pandanaboyana, John S Hammond, Rohan Thakkar, Fiona Oakley, Jelena Mann, Derek Mann, Niall Kenneth
Liver fibrosis is the excessive accumulation of extracellular matrix proteins that occurs in most chronic liver diseases. At the cellular level, liver fibrosis is associated with the activation of hepatic stellate cells (HSCs) which transdifferentiate into a myofibroblast-like phenotype that is contractile, proliferative and profibrogenic. HSC transdifferentiation induces genome-wide changes in gene expression that enable the cell to adopt its profibrogenic functions. We have previously identified that the deubiquitinase ubiquitin C-terminal hydrolase 1 (UCHL1) is highly induced following HSC activation, however, the cellular targets of its deubiquitinating activity are poorly defined...
May 29, 2024: Bioscience Reports
#3
JOURNAL ARTICLE
Yifan Wang, Xinyan Ma, Yanzheng Zou, Ming Yue, Meiling Zhang, Rongbin Yu, Hongbo Chen, Peng Huang
Despite achieving a high cure rate with direct-acting antivirals (DAAs) in hepatitis C treatment, further research is needed to identify additional benefits of the DAA therapy. The current study evaluated liver fibrosis improvement in 848 hepatitis C patients treated with DAAs, who also achieved sustained virologic response (SVR). Using the fibrosis-4 (FIB-4) index, patients were categorized based on their baseline fibrosis level, and improvements in fibrosis were analyzed in both the short-term (9-26 weeks) and long-term (≥ 36 weeks) follow-up...
March 21, 2024: Journal of Biomedical Research
#4
JOURNAL ARTICLE
Ahmet M Şahin, Murat Sayan, Sinan Çetin, Enes Telli, Mediha Uğur, Emsal Aydin, İlknur Şenel, Ünal Özek, Meltem A Yetkin
BACKGROUND: Although hepatitis B is vaccine-preventable, it remains a significant health problem. To the best of our knowledge, this is the first hepatitis B outbreak report from Türkiye. AIMS: To investigate the cause of hepatitis B outbreak in a nursing home for the disabled and make recommendations for prevention. METHODS: An outbreak of acute hepatitis B was declared in a nursing home for the disabled following the admission of 3 patients from the home in a hospital...
May 14, 2024: Eastern Mediterranean Health Journal
#5
JOURNAL ARTICLE
Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang'an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du
BACKGROUND AND AIMS: HBV-DNA integration in HBV-related hepatocellular carcinoma (HBV-HCC) can be targeted by HBV-specific T cells. SCG101 is an autologous, HBV-specific T-cell product expressing a T-cell receptor (TCR) after lentiviral transduction recognizing the envelope-derived peptide (S20-28) on HLA-A2. We here validated its safety and efficacy preclinically and applied it in an HBV-related HCC patient (NCT05339321). METHODS: GMP-grade manufactured cells were assessed for off-target reactivity and functionality against hepatoma cells...
May 29, 2024: Clinical and Molecular Hepatology
#6
Sandra E Pruitt, Jacob Filipek, Dustin Williford, Sara Sanders, Brittany Slagle, Heather Young, Jessica Snowden
Methicillin-resistant Staphylococcus aureus (MRSA) hepatic phlegmon is a rare cause of fever of unknown origin (FUO) in an immunocompetent patient from a high-income country (HIC). MRSA hepatic phlegmon is typically linked to protein malnutrition and chronic gastrointestinal infections in low- to middle-income countries while immunodeficiencies such as chronic granulomatous disease (CGD) are a more common cause in a HIC. Clinical manifestations of hepatic phlegmon can be vague and nonspecific making a complete FUO workup critical during evaluation...
April 2024: Curēus
#7
JOURNAL ARTICLE
Angelos Karelis, Magnus Jonsson, Jacob Budtz-Lilly, Wendela Jirström, Björn Sonesson, Nuno V Dias
PURPOSE: This study aimed to assess the feasibility and short-term outcomes of different manufactured proximal and distal stent graft components during fenestrated endovascular aortic repair (FEVAR). MATERIALS AND METHODS: A multicenter retrospective review was conducted at 3 aortic centers, involving all consecutive patients who underwent FEVAR utilizing a customized Dacron-based tubular proximal and a distal bifurcated polytetrafluoreten (PTFE)-based commercially available stent grafts...
May 28, 2024: Journal of Endovascular Therapy
#8
MULTICENTER STUDY
Mohamed Elbadry, Fathiya El-Raey, Mohamed Alboraie, Mohamed Abdel-Samiee, Doaa Abdeltawab, Mohammed Hussien Ahmed, Ahmed F Sherief, Ahmed Eliwa, Mina Tharwat, Amira Abdelmawgod, Ossama Ashraf Ahmed, Eman Abdelsameea, Aya Mahros, Abdelmajeed M Moussa, Alshaimaa Eid, Khaled Raafat, Ahmed Yousef, Saad A S Rafea, Youssef Alazzaq, Mohamed Mare'y, Ahmed Abdelaziz, El Sayed Abouzid Ibrahim, Waleed A Abd El Dayem, Ahmed A Abdelmoati, Ahmed Tawheed, Mohammad Amer, Samy Zaky, Mohamed El-Kassas
BACKGROUND: Egypt faces a significant public health burden due to chronic liver diseases (CLD) and peptic ulcer disease. CLD, primarily caused by Hepatitis C virus (HCV) infection, affects over 2.9% of the population nationwide, with regional variations. Steatotic liver disease is rapidly emerging as a significant contributor to CLD, especially in urban areas. Acid-related disorders are another widespread condition that can significantly impact the quality of life. These factors and others significantly influence the indications and findings of gastrointestinal endoscopic procedures performed in Egypt...
May 28, 2024: BMC Gastroenterology
#9
JOURNAL ARTICLE
Xiaoliang Zhu, Mengmeng Lin, Yuqian Chi, Xin Li, Ziyi Jiang, Xiaoyang Jian, Mengyuan Lian, Xiaodi Wu, Shuang Han, Xiaowei Shi
Qianggan capsule (QGC) is a complex preparation composed of 16 traditional Chinese medicines (TCM) that can clear heat and dampness, fortify the spleen and blood, typify qi and relieve depression. However, the chemical composition of QGC remains incompletely understood, despite its clinical use in treating chronic hepatitis and liver injury. The objective of this study was to explore the quality markers of QGC through qualitative and quantitative analysis of its chemical components. First, the chemical composition of QGC was qualitatively analyzed using UHPLC-Q-TOF-MS/MS...
May 23, 2024: Journal of Chromatography. A
#10
JOURNAL ARTICLE
Calvin Q Pan, Lin Zhu, Andy S Yu, Yuchan Zhao, Bo Zhu, Erhei Dai
OBJECTIVE: International guidelines recommend maternal tenofovir disoproxil fumarate (TDF) therapy accompanied by infant immunoprophylaxis to prevent HBV mother-to-child transmission (MTCT) in highly viremic mothers. However, pooled analyses for tenofovir alafenamide (TAF) effects and comparisons between the two regimens are lacking. DESIGN: In this meta-analysis, pairs of independent reviewers performed multiple database searches from inception to March 31, 2024, and extracted data from cohort studies and RCTs in highly viremic mothers...
May 28, 2024: Clinical Infectious Diseases
#11
JOURNAL ARTICLE
Yuji Ikeda, Ayato Murata, Hiroki Nago, Masahiro Yamaguchi, Rihwa Om, Yuichro Terai, Yuji Kita, Sho Sato, Shunsuke Sato, Yuji Shimada, Takuya Genda
AIM: Measurement of O-glycosylated middle hepatitis B surface antigen (HBsAg glycan isomer, HBsAgGi) has been developed to quantify hepatitis B virus (HBV) infectious virions and distinguish them from subviral particles. This study aimed to evaluate the association between serum HBsAg seroclearance and serum HBV virions measured by HBsAgGi in patients with chronic hepatitis B (CHB). METHODS: Serum HBsAgGi levels were quantified in 232 treatment-naïve patients with CHB genotype C...
May 28, 2024: Hepatology Research: the Official Journal of the Japan Society of Hepatology
#12
REVIEW
Roberta D'Ambrosio, Maria P Anolli, Nicola Pugliese, Chiara Masetti, Alessio Aghemo, Pietro Lampertico
In 2016, the Global Health Sector Strategy, ratified by the 69th World Health Assembly, set the ambitious goal of eliminating hepatitis C virus (HCV) and hepatitis B virus infections by 2030, emphasizing the importance of national screening programmes. Achieving this goal depends on each country's ability to identify and treat 80% of chronic hepatitis C cases, a critical threshold set by the World Health Organization. Traditionally, estimates of HCV prevalence have been based on interferon era studies that focused on high-risk subgroups rather than the general population...
May 28, 2024: Liver International: Official Journal of the International Association for the Study of the Liver
#13
REVIEW
Aditi Singh Thakur, Surekha Tayade, Nitish Batra, Neha Sethi, Arpita Jaiswal
Hepatitis B viral infection poses a significant challenge during pregnancy, as the risk of vertical transmission carries serious consequences for both maternal and neonatal well-being. This comprehensive review delves into the intricacies surrounding hepatitis B infection during the perinatal period, shedding light on its impact on pregnancy outcomes and stressing the necessity of addressing it within the broader framework of perinatal care. By scrutinizing current evidence, diagnostic methodologies, management techniques, and preventive measures, this review emphasizes the urgent need for enhanced screening protocols, timely interventions, and augmented public health initiatives...
April 2024: Curēus
#14
Khiet T Nguyen, Dat D Nguyen, Leidhy Montecinos, Pwint P Hlaing, Samridhi Khatri
Acute hepatitis can result from a wide variety of noninfectious causes that include, but are not limited to, drugs (drug-induced hepatitis), alcohol (alcoholic hepatitis), immunologic (autoimmune hepatitis, primary biliary cholangitis), or as a result of indirect insult secondary to biliary tract dysfunction (cholestatic hepatitis), pregnancy-related liver dysfunction, shock, or metastatic disease. In clinical settings, these causes are not uncommon to overlap with each other or are masked by obviously visible causes in medical history...
April 2024: Curēus
#15
Wajd Y Assahafi, Basil M Sindy, Yaser S Alqahtani, Abdulaziz H Albarakati, Wael Z Hossameldin
Recurrent pyogenic cholangitis (RPC), which is most commonly seen in Asian populations, is characterized by strictures and dilatation of both intrahepatic and extrahepatic bile ducts, along with the formation of pigmented stones inside the ducts. The most common symptoms are recurrent right upper quadrant pain, jaundice, and fever. Additionally, leukocytosis and elevated alkaline phosphatase and bilirubin levels may also be present. We report the case of a 43-year-old Bangladeshi male patient with a medical background of chronic hepatitis B infection and recurrent liver abscesses who presented to the emergency department with abdominal pain and fever lasting for two days...
April 2024: Curēus
#16
JOURNAL ARTICLE
Wei Fu, Zi Wei Deng, Pei Wang, Zhen Wang Zhu, Ye Pu, Zhi Bing Xie, Yong Zhong Li, Hong Ying Yu
BACKGROUND: Hepatitis B virus (HBV) infection can cause liver failure, while individuals with Acquired Immunodeficiency Virus Disease (AIDS) are highly susceptible to various opportunistic infections, which can occur concurrently. The treatment process is further complicated by the potential occurrence of immune reconstitution inflammatory syndrome (IRIS), which presents significant challenges and contributes to elevated mortality rates. CASE PRESENTATION: The 50-year-old male with a history of chronic hepatitis B and untreated human immunodeficiency virus (HIV) infection presented to the hospital with a mild cough and expectoration, revealing multi-drug resistant pulmonary tuberculosis (MDR-PTB), which was confirmed by XpertMTB/RIF PCR testing and tuberculosis culture of bronchoalveolar lavage fluid (BALF)...
May 27, 2024: BMC Infectious Diseases
#17
JOURNAL ARTICLE
Congjie Zhang, Zhenyu Shu, Shanshan Chen, Jiaxuan Peng, Yueyue Zhao, Xuan Dai, Jie Li, Xuehan Zou, Jianhua Hu, Haijun Huang
Early assessment and accurate staging of liver fibrosis may be of great help for clinical diagnosis and treatment in patients with chronic hepatitis B (CHB). We aimed to identify serum markers and construct a machine learning (ML) model to reliably predict the stage of fibrosis in CHB patients. The clinical data of 618 CHB patients between February 2017 and September 2021 from Zhejiang Provincial People's Hospital were retrospectively analyzed, and these data as a training cohort to build the model. Six ML models were constructed based on logistic regression, support vector machine, Bayes, K-nearest neighbor, decision tree (DT) and random forest by using the maximum relevance minimum redundancy (mRMR) and gradient boosting decision tree (GBDT) dimensionality reduction selected features on the training cohort...
May 27, 2024: Scientific Reports
#18
JOURNAL ARTICLE
Qian Liu, Futing Liu, Wanlu Duan, Yu Wei, Tingdong Zhou, Hao Zhang, Zhi Duan, Qiang Zhou, Qin Wang
OBJECTIVE: Interferon-α (IFNα) therapy has been an integral part of the current treatment for hepatitis B virus (HBV) infection. However, the exact effect of IFNα antiviral therapy on liver function and iron metabolism in patients with chronic hepatitis B (CHB) remains unclear. Here, we investigated the characteristics of changes in liver function and iron metabolism indexes in patients with chronic hepatitis B before and after IFNα treatment. Additionally, we determined their predictive value for the therapeutic response of IFNα treatment...
March 2024: Annals of Clinical and Laboratory Science
#19
JOURNAL ARTICLE
Loreta A Kondili, Giuseppina Brancaccio, Maria Elena Tosti, Barbara Coco, Maria Giovanna Quaranta, Vincenzo Messina, Alessia Ciancio, Filomena Morisco, Valentina Cossiga, Ernesto Claar, Valerio Rosato, Marianna Ciarallo, Irene Cacciola, Francesca Romana Ponziani, Lucia Cerrito, Roberta Coppola, Francesco Longobardi, Elisa Biliotti, Alessia Rianda, Francesco Barbaro, Nicola Coppola, Maria Stanzione, Francesco Barchiesi, Stefano Fagiuoli, Mauro Viganò, Marco Massari, Francesco Paolo Russo, Alberto Ferrarese, Diletta Laccabue, Vito Di Marco, Pierluigi Blanc, Aldo Marrone, Giulia Morsica, Alessandro Federico, Donatella Ieluzzi, Alba Rocco, Francesco Giuseppe Foschi, Alessandro Soria, Ivana Maida, Luchino Chessa, Michele Milella, Elena Rosselli Del Turco, Salvatore Madonia, Liliana Chemello, Ivan Gentile, Pierluigi Toniutto, Matteo Bassetti, Lorenzo Surace, Leonardo Baiocchi, Adriano Pellicelli, Adriano De Santis, Massimo Puoti, Elisabetta Degasperi, Grazia Anna Niro, Anna Linda Zignego, Antonio Craxi, Giovanni Raimondo, Teresa Antonia Santantonio, Maurizia Rossana Brunetto, Giovanni Battista Gaeta, On Behalf Of Piter Collaborating Investigators
BACKGROUND AND AIMS: We aimed to characterize the epidemiologic and comorbidities profiles of patients with chronic Hepatitis D (CHD) followed in clinical practice in Italy and explored their interferon (IFN) eligibility. METHODS: This was a cross-sectional study of the PITER cohort consisting of consecutive HBsAg-positive patients from 59 centers over the period 2019-2023. Multivariable analysis was performed by logistic regression model. RESULTS: Of 5,492 HBsAg-positive enrolled patients, 4,152 (75...
May 25, 2024: International Journal of Infectious Diseases: IJID
#20
JOURNAL ARTICLE
Nagisa Hara, Atsushi Hiraoka, Masato Nakai, Makoto Shiraki, Tadashi Namisaki, Hisamitsu Miyaaki, Takuro Hisanaga, Hirokazu Takahashi, Hideko Ohama, Fujimasa Tada, Naoya Sakamoto, Kazuhiko Nakao, Taro Takami, Yuichiro Eguchi, Hitoshi Yoshiji
AIM: It is not uncommon to encounter outpatients in the hepatology department with harmful alcohol habits. When treating such chronic liver disease (CLD) patients, an adequate intervention method for harm reduction of alcohol use, such as brief intervention (BI) or BI and nalmefene, should be considered. This study aimed to elucidate the clinical effectiveness of BI for CLD patients affected by harmful alcohol use. METHODS: From June 2021 to 2023, 123 Japanese CLD outpatients (hepatitis B virus : hepatitis C virus : alcoholic liver disease : others = 32:18:42:31) with an Alcohol Use Disorders Identification Test (AUDIT) score of ≥8 at the initial interview and a repeat interview with AUDIT 9 months later were enrolled...
May 27, 2024: Hepatology Research: the Official Journal of the Japan Society of Hepatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
